2026 ICD-10-CM Diagnosis Code C79.63Secondary malignant neoplasm of bilateral ovaries

ICD-10-CM Codes›C00–D49›C76-C80›C79

ICD-10-CM C79.63
CMSSource: CMS FY 2026 ICD-10-CM dataset · Effective Oct 1, 2025 – Sep 30, 2026

C79.63 is a billable ICD-10-CM diagnosis code for secondary malignant neoplasm of bilateral ovaries. It is valid on HIPAA claims for fiscal year 2026 (October 1, 2025 through September 30, 2026) and groups to MS-DRG 736 through 741, 754 through 756. Coders also document this condition as bilateral metastatic malignant neoplasm to ovaries. In AHRQ's Clinical Classifications Software (CCSR), this diagnosis falls under Secondary malignancies.

Code Identity

ICD-10-CM Code
C79.63
Billable Status
Yes — Valid for Submission
Code Describes
Secondary malignant neoplasm of bilateral ovaries
Short Description
Secondary malignant neoplasm of bilateral ovaries
Same as the full description in the CMS dataset.
Parent Code
C79.6
Secondary malignant neoplasm of ovary

Code Classification

ChapterC00–D49Neoplasms
SectionC76-C80Malignant neoplasms of ill-defined, other secondary and unspecified sites
CategoryC79Secondary malignant neoplasm of other and unspecified sites
This CodeC79.63Secondary malignant neoplasm of bilateral ovaries

Approximate SynonymsGuidance

Alternate terms and clinical phrases that map to this code.

  • Bilateral metastatic malignant neoplasm to ovaries
  • Metastatic malignant neoplasm to left ovary
  • Metastatic malignant neoplasm to ovary
  • Metastatic malignant neoplasm to right ovary

Clinical ClassificationClinical

AHRQ’s CCSR groups this code into broader clinical categories.

CCSR NEO070
Secondary malignancies
Default principal diagnosis: inpatient Yes · outpatient Yes

Table of NeoplasmsClinical

Anatomical sites in the Table of Neoplasms that reference this code family.

SiteMalig.
Primary		Malig.
Secondary		Ca
in situ		BenignUncertainUnspec.
corpusC56.C79.6D07.39D27.D39.1D49.59
corpus › albicansC56.C79.6D07.39D27.D39.1D49.59
ovaryC56.C79.6D07.39D27.D39.1D49.59

Patient EducationClinical

Ovarian Cancer

Cancer is a disease in which abnormal cells in the body grow out of control and form a tumor. Ovarian cancer is a cancerous tumor that forms in the tissues of an ovary. The ovaries are a pair of female reproductive glands that make eggs and female hormones.

The full article covers:

  • What is ovarian cancer?
  • What are the types of ovarian cancer?
  • What causes ovarian cancer?
  • Who is more likely to develop ovarian cancer?
  • What are the symptoms of ovarian cancer?
  • How is ovarian cancer diagnosed?
  • What are the treatments for ovarian cancer?

Read the full article at MedlinePlus

Courtesy of MedlinePlus, a service of the U.S. National Library of Medicine.

Code History & ChangesHistory

Replacement C79.63 replaces the following previously assigned code(s):

  • C79.61 - Secondary malignant neoplasm of right ovary
  • C79.62 - Secondary malignant neoplasm of left ovary
FY 2022AddedAdded to the ICD-10-CM code setEffective October 1, 2021.
FY 2023–2025No changes
FY 2026CurrentCurrent code set, no changesEffective October 1, 2025 through September 30, 2026.

Questions About C79.63Overview

Is C79.63 (Secondary malignant neoplasm of ovary) a billable code?

Yes. This is a billable ICD-10-CM code, specific enough to report secondary malignant neoplasm of bilateral ovaries on HIPAA-covered claims from October 1, 2025 through September 30, 2026.

What MS-DRG does C79.63 group to?

When secondary malignant neoplasm of bilateral ovaries is the principal diagnosis on an inpatient stay, it groups to MS-DRG 736, 737, 738, 739, 740, 741, 754, 755, 756, with relative weights from 0.9605 to 3.5745 depending on complications. Higher weights mean higher Medicare reimbursement.

Footnotes

[1] Chronic - a chronic condition code indicates a condition lasting 12 months or longer and its effect on the patient based on one or both of the following criteria:

  • The condition results in the need for ongoing intervention with medical products,treatment, services, and special equipment
  • The condition places limitations on self-care, independent living, and social interactions.